von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

von Willebrand Disease (vWD) Market Report Overview

The von Willebrand Disease (vWD) market size in the three major markets (3MM) (US, Germany, and UK) was $892 million in 2022. The vWD market will register a CAGR of more than 8% from 2022 to 2032. The vWD market research report offers an overview of vWD, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications for the vWD therapeutics market.

vWD Market Outlook 2022-2032 ($ Million)

vWD Market Outlook 2022-2032 ($ Million)

Buy the Full Report to Know More About vWD Market Forecast, Download a Free Sample Report

von Willebrand Disease (vWD) is the most inherited blood-clotting disorder. It arises from a deficiency in the quality or quantity of von Willebrand factor (vWF), a multimeric protein required for platelet adhesion. There are three types of hereditary vWD—type 1, type 2, and type 3—of which type 2 contains various subtypes (2A, 2B, 2M, and 2N).

Market Size (2022) $892 million
CAGR (2022-2032) >8%
Key Countries (3MM) ·        The US

·        UK

·        Germany

Key Drugs ·        Koate DVI

·        Wilfactin

·        Vonvendi

·        Desmopressin Acetate

·        Immunate

·        Wilate

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

vWD Market Dynamics

  • The vWD market is expected to have two novel entrants across the forecast period. These include vWF recombinant for pediatric use and BT-200, an RNA oligonucleotide targeting type 2 vWD. These novel therapies will provide significant opportunities to address the need for long-term, efficacious therapies.
  • The entrance of RNA oligonucleotide and vWF recombinant for children will likely increase the treatment options for more challenging and severe types of vWD. This will increase the vWD market size as a greater number of patients will have access to treatment.

vWD Market Segmentation by Country

The key countries in the vWD market are the US, UK, and Germany. In 2022, the US dominated the total vWD market in the 3MM occupying over 80% of the market share. The US’s market dominance is due to the higher price of pharmaceuticals in the US and the high diagnosed prevalence of vWD in the country compared to the other major markets.

vWD Market Analysis by Country, 2022 (%)

vWD Market Analysis by Country, 2022 (%)

Buy the Full Report for Country-Wise Insights on the vWD Market, Download a Free Sample Report

vWD Market Segmentation by Drugs

The key drugs in the vWD market are Koate DVI, Wilfactin, Vonvendi, Desmopressin Acetate, Immunate, Wilate, Fanhdi, Alphanate, and Voncento among others. In 2022, Vonvendi accounted for the highest sales. Vonvendi is a vWF recombinant therapy that directly addresses the underlying vWF deficiency causing the disease. This drug development is currently in Phase III in the US and pre-registration in the EU.

vWD Market Analysis by Drugs, 2022 (%)

vWD Market Analysis by Drugs, 2022 (%)

Buy the Full Report for Drug-Wise Insights on the vWD Market, Download a Free Sample Report

Segments Covered in this Report

vWD Country Outlook ($ Million, 2022-2032)

  • The US
  • The UK
  • Germany

vWD Drugs Outlook (%, 2022-2032)

  • Koate DVI
  • Wilfactin
  • Vonvendi
  • Desmopressin Acetate
  • Immunate
  • Wilate


  • Annualized vWD therapeutics market revenue in 3MM (the US, Germany, and the UK), the annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032 covering three-time points: base year, 5-year, and 10-year.
  • Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for vWD treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 3MM vWD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

Key Highlights

Report deliverables include a Pdf report and Excel-based forecast model

Forecast includes three countries: US, Germany, and the UK

Forecasts cover three time points: base year, 5-year, and 10-year

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the vWD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the vWD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Kedrion Biopharma
Grifols SA
CSL Behring LLC
Bio Products Laboratory Ltd
Ferring International Center SA
Sun Pharmaceutical Industries
Dr. Reddy's Laboratories
United Biomedical/Athenax Inc.
Teva Pharmaceutical Industries Ltd

Table of Contents

1 Executive Summary

1.1 Executive Summary

2 Disease Overview

2.1 Overview of von Willebrand Disease

2.2 Classification of von Willebrand Disease

3 Epidemiology

3.1 Diagnosed Prevalent Cases of Cushing’s Syndrome, 2020–2030

3.2 Sources and Methodology

4 Current Treatment Options

4.1 Treatment Paradigm

4.2 Marketed Products

4.3 Product Profiles: Plasma-Derived FVIII, Plasma Derived vWF, Coagulation Factor VIII (Human) + von Willebrand Factor Complex (Human), Desmopressin Acetate, Vonvendi (US)/Veyvondi (EU) (For Adult Use)

5 Unmet Needs and Opportunities

5.1 Unmet Needs in von Willebrand Disease

5.2 Improved Therapies for Severe vWD

5.3 Better Diagnostic Tools

5.4 Increased Patient and Physician Education

5.5 Addressing Health Disparities

5.6 Cost-Effective Therapies

6 Pipeline Assessment

6.1 von Willebrand Disease Pipeline Overview

6.2 Leading Pipeline Agents

6.3 Product Profile:. Vonvendi (US)/Veybondi (EU) (For Pediatric Use), Takeda

6.4 Product Profile: BT-200 – Guardian Therapeutics

6.5 Review Designations

6.6 von Willebrand Disease: Clinical Trials (Phase II/III) Overview

7 R&D Strategies

7.1 Trends in Clinical Trial Design in von Willebrand Disease

7.2 Trends in Deal-Making in von Willebrand Disease

8 Market Outlook

8.1 von Willebrand Disease Sales Forecast

8.2 von Willebrand Disease Market Forecast

8.3 Market Drivers and Barriers

9 Appendix

9.1 Primary Research: KOL Information

9.2 About the Authors

10 Contact Us

Frequently asked questions

von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Innovation in pharma: transdermal drug delivery
$250 | November 2023
Synthetic Biology - Thematic Intelligence
$995 | November 2023
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032 in real time.

  • Access a live von Willebrand Disease (vWD) Market Opportunity Assessment, Epidemiology, Disease Management, Clinical Trials, Unmet Needs and Forecast to 2032 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.